Research programme: pain therapeutics - Flexion Therapeutics

Drug Profile

Research programme: pain therapeutics - Flexion Therapeutics

Alternative Names: FX 007

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Flexion Therapeutics
  • Class Analgesics
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Musculoskeletal pain
  • Discontinued Postoperative pain

Most Recent Events

  • 10 Mar 2017 Discontinued - Preclinical for Postoperative pain in USA (Intra-articular)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Musculoskeletal-pain in USA (Intra-articular, Injection)
  • 11 Mar 2016 Flexion Therapeutics has licensed issued patent protection for FX 007 in USA and other countries (Flexion Therapeutics 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top